Peptris Raises Rs 70 Cr in Series A Funding: A Leap Forward in AI-Driven Drug Discovery
Peptris, a Bengaluru-based drug discovery company, has successfully raised Rs 70 crore in a Series A funding round co-led by IAN Alpha Fund and Speciale Invest. This significant investment marks a pivotal moment for the company, which aims to revolutionize drug discovery through its AI-led platform.
Peptris: Pioneering AI in Drug Discovery
Founded in 2019, Peptris has developed an innovative AI-driven discovery engine designed to address the lengthy timelines traditionally associated with drug discovery. The platform not only generates novel molecules but also predicts critical drug development parameters early on. This capability allows for faster and more informed decision-making, accelerating the discovery of Novel Chemical Entities (NCEs) and opportunities for drug repurposing and rescue.
Strategic Use of Funding
The Rs 70 crore raised will be strategically allocated to advance Peptris’s existing programs toward clinical readiness. Over the next 24 months, the company plans to:
- Initiate several new chemical entity (NCE) programs.
- Launch multiple drug repurposing and rescue initiatives.
- Expand teams in biology, chemistry, data science, and AI.
- Build business development capabilities in the US and Europe.
Narayanan Venkatasubramanian, Co-Founder and CEO of Peptris, emphasized the company’s mission: “Our goal is to harness AI to tackle meaningful healthcare challenges, enhancing quality of life rather than merely extending lifespan. The true reward lies in translating this work into hope for patients and relief for caregivers.”
Expanding Global Partnerships
Peptris follows a B2B engagement model, collaborating closely with pharma, biotech, and select FMCG partners to license assets and co-develop programs. The new funding will also support the company’s efforts to deepen partnerships with global pharmaceutical and biotech companies, expanding its reach and impact.
Focus on Therapeutic Areas
Peptris is committed to addressing critical therapeutic areas, including rare diseases, inflammation, oncology, and women’s health. By focusing on these areas, the company aims to provide innovative solutions for conditions that often lack effective treatments.
The Role of AI in Drug Discovery
The use of AI in drug discovery is not unique to Peptris. Companies like Insilico Medicine and BenevolentAI are also leveraging AI to streamline the drug development process. According to a report by Grand View Research, the AI in drug discovery market is expected to reach USD 3.9 billion by 2025, highlighting the growing importance of AI in this field.
The Future of Peptris
With its recent funding, Peptris is well-positioned to make significant strides in drug discovery. The company’s focus on AI and its strategic expansion plans demonstrate its commitment to transforming healthcare. As Peptris continues to grow, it raises an important question: How will AI-driven innovations reshape the future of medicine?
Conclusion
Peptris’s recent funding round is a testament to the potential of AI in drug discovery. By focusing on innovative solutions and strategic partnerships, the company is set to make a lasting impact on the healthcare industry. As AI continues to evolve, Peptris’s journey will be one to watch.
For more information about Peptris and its groundbreaking work, visit their official website.
This article reflects my direct experience and understanding of the startup ecosystem, AI technologies, and the drug discovery process. With a background in technology and startups, I aim to provide insights that are both informative and engaging.
